@article{oai:repo.qst.go.jp:00047097,
 author = {Ito, Hiroshi and Shinotoh, Hitoshi and Shimada, Hitoshi and Miyoshi, Michie and Yanai, Kazuhiko and Okamura, Nobuyuki and Takano, Harumasa and Takahashi, Hidehiko and Arakawa, Ryosuke and Kodaka, Fumitoshi and Ono, Maiko and Eguchi, Yoko and Higuchi, Makoto and Fukumura, Toshimitsu and Suhara, Tetsuya and 伊藤 浩 and 島田 斉 and 三好 美智恵 and 岡村 信行 and 高野 晴成 and 高橋 英彦 and 荒川 亮介 and 小高 文聰 and 小野 麻衣子 and 江口 洋子 and 樋口 真人 and 福村 利光 and 須原 哲也},
 issue = {4},
 journal = {European journal of nuclear medicine and molecular imaging},
 month = {Nov},
 note = {The characteristic neuropathological changes in Alzheimer's disease (AD) are deposition of amyloid senile plaques and neurofibrillary tangles. The (18)F-labeled amyloid tracer, [(18)F]2-[(2-{(E)-2-[2-(dimethylamino)-1,3-thiazol-5-yl]vinyl}-1,3-benzoxazol-6-yl)oxy]-3-fluoropropan-1-ol (FACT), one of the benzoxazole derivatives, was recently developed. In the present study, deposition of amyloid senile plaques was measured by positron emission tomography (PET) with both [(11)C]Pittsburgh compound B (PIB) and [(18)F]FACT in the same subjects, and the regional uptakes of both radiotracers were directly compared.},
 pages = {745--754},
 title = {Imaging of amyloid deposition in human brain using positron emission tomography and [(18)F]FACT: comparison with [ (11)C]PIB.},
 volume = {41},
 year = {2013}
}